Prognostic significance of proliferation activity and neuroendocrine differentiation to predict treatment failure after radical prostatectomy

References

• Epstein JI, Amin M, Boccon-Gibod L, Egevad L, Humphrey PA, Mikuz G, et al. Prognostic factors and reporting of prostate carcinoma in radical prostatectomy and pelvic lymphadenectomy specimens. Scand J Urol Nephrol Suppl 2005; 216: 34–63
   Google Scholar
• Taftachi R, Ayhan A, Ekici S, Ergen A, Ozen H. Proliferating-cell nuclear antigen (PCNA) as an independent prognostic marker in patients after prostatectomy: a comparison of PCNA and Ki-67. BJU Int 2005; 95: 650–4
   PubMed Web of Science ®Google Scholar
• Inoue T, Segawa T, Shiraishi T, Yoshida T, Toda Y, Yamada T, et al. Androgen receptor, Ki67, and p53 expression in radical prostatectomy specimens predict treatment failure in Japanese population. Urology 2005; 66: 332–7
   PubMed Web of Science ®Google Scholar
• Sanchez KM, Sweeney CJ, Mass R, Koch MO, Eckert GJ, Geary WA, et al. Evaluation of HER-2/neu expression in prostatic adenocarcinoma: a requested [sic.] for a standardized, organ specific methodology. Cancer 2002; 95: 1650–5
   PubMed Web of Science ®Google Scholar
• Segawa N, Mori I, Utsunomiya H, Nakamura M, Nakamura Y, Shan L, et al. Prognostic significance of neuroendocrine differentiation, proliferation activity and androgen receptor expression in prostate cancer. Pathol Int 2001; 51: 452–9
   PubMed Web of Science ®Google Scholar
• Rubio J, Ramos D, Lopez-Guerrero JA, Iborra I, Collado A, Solsona E, et al. Immunohistochemical expression of Ki-67 antigen, cox-2 and Bax/Bcl-2 in prostate cancer; prognostic value in biopsies and radical prostatectomy specimens. Eur Urol 2005; 48: 745–51
   PubMed Web of Science ®Google Scholar
• Resnick MI, Gospodarowicz M, Boccon-Gibod L, Brawer M, Kattan M, Wein A, . Markers and prognostic factors (Committee 2). Prostate Cancer, L Denis, G Bartsch, S Khoury, M Murai, A Partin, et al. Proc 3rd International Consultation on Prostate Cancer; Health Publications, Paris 2003; 49–89
   Google Scholar
• Ahlgren G, Pedersen K, Lundberg S, Aus G, Hugosson J, Abrahamsson P. Neuroendocrine differentiation is not prognostic of failure after radical prostatectomy but correlates with tumor volume. Urology 2000; 56: 1011–5
   PubMed Web of Science ®Google Scholar
• Bantis A, Giannopoulos A, Gonidi M, Liossi A, Aggelonidou E, Petrakakou E, et al. Expression of p120, Ki-67 and PCNA as proliferation biomarkers in imprint smears of prostate carcinoma and their prognostic value. Cytopathology 2004; 15: 25–31
   PubMed Web of Science ®Google Scholar
• Di Sant'Agnese PA, Cockett AT. Neuroendocrine differentiation in prostatic malignancy [Review]. Cancer 1996; 78: 357–61
   PubMed Web of Science ®Google Scholar
• Di Sant’ Agnese PA. Neuroendocrine differentiation in carcinoma of the prostate. Diagnostic, prognostic, and therapeutic implications [Review]. Cancer 1992;70(1 Suppl):254–68.
   PubMed Web of Science ®Google Scholar
• Di Sant'Agnese PA, de Mesy Jensen KL. Neuroendocrine differentiation in prostatic carcinoma. Hum Pathol 1987; 18: 849–56
   PubMed Web of Science ®Google Scholar
• Yu DS, Hsieh DS, Chang SY. Modulation of prostate carcinoma cell growth and apoptosis by chromogranin A. J Urol 2003; 170: 2031–5
   PubMed Web of Science ®Google Scholar
• Grobholz R, Griebe M, Sauer CG, Michel MS, Trojan L, Bleyl U. Influence of neuroendocrine tumor cells on proliferation in prostatic carcinoma. Hum Pathol 2005; 36: 562–70
   PubMed Web of Science ®Google Scholar
• Gould VE, Wiedenmann B, Lee I, Schwechheimer K, Dockhorn-Dworniczak B, Radosevich JA, et al. Synaptophysin expression in neuroendocrine neoplasms as determined by immunocytochemistry. Am J Pathol 1987; 126: 243–57
   PubMed Web of Science ®Google Scholar
• Weinstein MH, Partin AW, Veltri RW, Epstein JI. Neuroendocrine differentiation in prostate cancer: enhanced prediction of progression after radical prostatectomy. Hum Pathol 1996; 27: 683–7
   PubMed Web of Science ®Google Scholar
• Di Sant'Agnese PA. Neuroendocrine differentiation in prostatic carcinoma: an update on recent developments [Review]. Ann Oncol 2001; 12(Suppl 2)S135–40
   PubMedGoogle Scholar
• Yu DS, Hsieh DS, Chen HI, Chang SY. The expression of neuropeptides in hyperplastic and malignant prostate tissue and its possible clinical implications. J Urol 2001; 166: 871–5
   PubMed Web of Science ®Google Scholar
• Cohen MK, Arber DA, Coffield KS, Keegan GT, McClintock J, Speights VO, Jr. Neuroendocrine differentiation in prostatic adenocarcinoma and its relationship to tumor progression. Cancer 1994; 74: 1899–903
   PubMed Web of Science ®Google Scholar
• Noordzij MA, van der Kwast TH, van Steenbrugge GJ, Hop WJ, Schroder FH. The prognostic influence of neuroendocrine cells in prostate cancer: results of a long-term follow-up study with patients treated by radical prostatectomy. Int J Cancer 1995; 62: 252–8
   PubMed Web of Science ®Google Scholar
• Cattoretti G, Becker MH, Key G, Duchrow M, Schluter C, Galle J, et al. Monoclonal antibodies against recombinant parts of the Ki-67 antigen (MIB 1 and MIB 3) detect proliferating cells in microwave-processed formalin-fixed paraffin sections. J Pathol 1992; 168: 357–63
   PubMed Web of Science ®Google Scholar
• Munoz E, Gomez F, Paz JI, Casado I, Silva JM, Corcuera MT, et al. Ki-67 immunolabeling in pre-malignant lesions and carcinoma of the prostate. Histological correlation and prognostic evaluation. Eur J Histochem 2003; 47: 123–8
   PubMed Web of Science ®Google Scholar
• Thompson SJ, Mellon K, Charlton RG, Marsh C, Robinson M, Neal DE. P53 and Ki-67 immunoreactivity in human prostate cancer and benign hyperplasia. Br J Urol 1992; 69: 609–13
   PubMedGoogle Scholar
• Bubendorf L, Sauter G, Moch H, Schmid HP, Gasser TC, Jordan P, et al. Ki67 labelling index: an independent predictor of progression in prostate cancer treated by radical prostatectomy. J Pathol 1996; 178: 437–41
   PubMed Web of Science ®Google Scholar
• Bubendorf L, Tapia C, Gasser TC, Casella R, Grunder B, Moch H, et al. Ki67 labeling index in core needle biopsies independently predicts tumor-specific survival in prostate cancer. Hum Pathol 1998; 29: 949–54
   PubMed Web of Science ®Google Scholar
• Bettencourt MC, Bauer JJ, Sesterhenn IA, Mostofi FK, McLeod DG, Moul JW. Ki-67 expression is a prognostic marker of prostate cancer recurrence after radical prostatectomy. J Urol 1996; 156: 1064–8
   PubMed Web of Science ®Google Scholar
• Coetzee LJ, Layfield LJ, Hars V, Paulson DF. Proliferative index determination in prostatic carcinoma tissue: is there any additional prognostic value greater than that of Gleason score, ploidy and pathological stage?. J Urol 1997; 157: 214–8
   PubMed Web of Science ®Google Scholar
• Vis AN, Noordzij MA, Fitoz K, Wildhagen MF, Schroder FH, van der Kwast TH. Prognostic value of cell cycle proteins p27(kip1) and Ki-67, and the cell adhesion protein CD44s in surgically treated patients with prostate cancer. J Urol 2000; 164: 2156–61
   PubMed Web of Science ®Google Scholar